Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Paediatric Disease Designation (RPDD) as well as Orphan Drug Designation (ODD) for the treatment of Legg-Calvé-Perthes Disease (LCPD).
STOCKHOLM, April 25, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease Designation (RPDD) as well as Orphan Drug Designation (ODD) for the treatment of Legg-Calvé-Perthes Disease (LCPD).
STOCKHOLM, April 23, 2024 /PRNewswire/ -- Medivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today an update from a Type C meeting with the FDA, regarding the company's plans for a global phase 2b study and opening of an IND for fostroxacitabine bralpamide (fostrox) in the US.
STOCKHOLM, April 15, 2024 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its partner Vetbiolix, a veterinary biotechnology company based in France, reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.
STOCKHOLM, April 9, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Investing in Oncology Forum on April 10, 2024.
STOCKHOLM, April 4, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company's website: www.medivir.com.
Medivir to present at the Life Science Day in Gothenburg on March 6
Medivir announces the outcome of the directed share issue
STOCKHOLM, Jan. 24, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024.
STOCKHOLM, Jan. 23, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, invites to a conference call on the updated data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma (HCC). The data was presented at the ASCO (American Society of Clinical Oncology) GI (Gastrointestinal Cancers) Symposium in San Francisco on January 19. The conference call will be held today January 23, at 14.00 CET, to update on the results in the study and the plans moving forward, including feedback from extensive interactions with world renowned experts at the ASCO GI congress.